Abstract:BackgroundThe efficacy of heparins and low-MW-heparins (LMWH) against human asthma has been known for decades. However, the clinical utility of these compounds has been hampered by their anticoagulant properties. Much effort has been put into harnessing the anti-inflammatory properties of LMWH but none have been used as therapy for asthma. Sulfated-non-anticoagulant heparin (S-NACH) is an ultra-LMWH with no systemic anticoagulant effects.ObjectiveThe present study explored the potential of S-NACH in blocking allergic asthma and examined the potential mechanism by which it exerts its effects.MethodsAcute and chronic ovalbumin-based mouse models of asthma, splenocytes, and a lung epithelial cell line were used. Mice were challenged with aerosolized ovalbumin and administered S-NACH or saline 30 min after each ovalbumin challenge.ResultsSulfated-non-anticoagulant heparin administration in mice promoted a robust reduction in airway eosinophilia, mucus production, and airway hyperresponsiveness even after chronic repeated challenges with ovalbumin. Such effects were linked to suppression of Th2 cytokines IL-4/IL-5/IL-13/GM-CSF and ovalbumin-specific IgE without any effect on IFN-γ. S-NACH also reduced lung fibrosis in mice that were chronically-exposed to ovalbumin. These protective effects of S-NACH may be attributed to modulation of the IL-4/JAK1 signal transduction pathway through an inhibition of STAT6 phosphorylation and a subsequent inhibition of GATA-3 and inducible NO synthase expression. The effect of the drug on STAT6 phosphorylation coincided with a reduction in JAK1 phosphorylation upon IL-4 treatment. The protective effects of S-NACH treatment was associated with reduction of the basal expression of the two isoforms of arginase ARG1 and ARG2 in lung epithelial cells.ConclusionsOur study demonstrates that S-NACH constitutes an opportunity to benefit from the well-known anti-asthma properties of heparins/LMWH while bypassing the risk of bleeding. Our results show, for the first time, that such anti-asthma effects may be associated with reduction of the IL-4/JAK1/STAT6 pathway.

Arthropod-Derived Histamine-Binding Protein Prevents Murine Allergic Asthma

Arthropod-Derived Protein Ev131 Inhibits Histamine Action and Allergic Asthma

Histamine Scavenging Attenuates Endotoxin-Induced Acute Lung Injury

Interleukin-17 Orchestrates the Granulocyte Influx into Airways after Allergen Inhalation in A Mouse Model of Allergic Asthma

The Effects Of Overexpression Of Histamine Releasing Factor (Hrf) In A Transgenic Mouse Model

Potential regulatory effects of histamine by intracerebroventricularly administration on asthma-like reaction in rats

Neutralization of either IL-17A or IL-17F is sufficient to inhibit house dust mite induced allergic asthma in mice.

Antibodies Specific for a Segment of Human Membrane IgE Deplete IgE-producing B Cells in Humanized Mice.

Dihydroartemisinin Suppresses Ovalbumin-Induced Airway Inflammation in a Mouse Allergic Asthma Model

Anti-HMGB1 Neutralizing Antibody Ameliorates Neutrophilic Airway Inflammation by Suppressing Dendritic Cell-Mediated Th17 Polarization

Immunomodulatory innate defence regulator (IDR) peptide alleviates airway inflammation and hyper-responsiveness

Acetamide-45 Inhibited Hyperresponsiveness and Airway Inflammation in Mice Partly Depending on Phosphodiesterase Activity Suppression

Ethyl pyruvate attenuates murine allergic rhinitis partly by decreasing high mobility group box 1 release.

Systemic Lack of Canonical Histamine Receptor Signaling Results in Increased Resistance to Autoimmune Encephalomyelitis

Recombinant HMGB1 A box protein inhibits Th17 responses in mice with neutrophilic asthma by suppressing dendritic cell-mediated Th17 polarization

Human C-C Chemokine Receptor 3 Monoclonal Antibody Inhibits Pulmonary Inflammation in Allergic Mice

Soluble IL-4 Receptor Inhibits Airway Inflammation Following Allergen Challenge in a Mouse Model of Asthma1

Neutralizing Oxidized Phosphatidylcholine Reduces Airway Inflammation and Hyperreactivity in a Murine Model of Allergic Asthma

Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway

Anti-Cd69 Monoclonal Antibody Treatment Inhibits Airway Inflammation in A Mouse Model of Asthma

Modulation of Lung Inflammation by Vessel Dilator in a Mouse Model of Allergic Asthma.